Current Rheumatology Reports

, Volume 6, Issue 5, pp 351–356 | Cite as

Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: Possible interactions and implications for treatment of rheumatoid arthritis

  • Tobias Kurth
  • Charles H. Hennekens
  • Julie E. Buring
  • J. Michael Gaziano
Article

Abstract

Aspirin, nonsteroidal antiinflammatory drugs (NSAIDs), and cyclooxygenase-2 (COX-2) inhibitors are widely used in patients with rheumatoid arthritis. Aspirin has the largest and most persuasive body of randomized trial evidence to support its use in secondary prevention for cardiovascular disease (CVD) and primary prevention for myocardial infarction. There is, however, a possible deleterious interaction between aspirin and NSAIDs on CVD that requires further research. Aspirin, NSAIDs, and to a lesser extent COX-2 inhibitors are associated with increased gastrointestinal side effects and bleeding, alone and in combination. The more widespread and appropriate use of aspirin in patients with rheumatoid arthritis will avoid many premature deaths in secondary prevention for CVD and first myocardial infarctions in primary prevention.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Williams A, Hennekens CH: The role of aspirin in cardiovascular diseases--forgotten benefits? Expert Opin Pharmacother 2004, 5:109- 115.PubMedGoogle Scholar
  2. 2.
    Laine L: Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120:594- 606.PubMedCrossRefGoogle Scholar
  3. 3.
    Spiegel BM, Targownik L, Dulai GS, Gralnek IM: The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003, 138:795- 806.PubMedGoogle Scholar
  4. 4.
    Hennekens CH: Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 1998, 97:1095- 1102.PubMedGoogle Scholar
  5. 5.
    Hennekens CH, Buring JE: Epidemiology in medicine. Boston, Toronto: Little Brown; 1987.Google Scholar
  6. 6.
    Antithrombotic Trialists’ Collaboration: Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002, 324:71- 86. Third and most recent meta-analysis on the role of aspirin and other antiplatelet therapy in CVD prevention. This study excellently summarizes the totality of randomized evidence that antiplatelet therapy, in particular aspirin, is highly effective in the prevention of CVD in high-risk patients.CrossRefGoogle Scholar
  7. 7.
    Eidelman RS, Hebert PR, Weisman SM, Hennekens CH: An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003, 163:2006- 2010. Meta-analysis that summarizes the totality of randomized evidence regarding aspirin’s role in primary prevention for MI. The study provides strong support that aspirin reduces the risk for first MI in healthy individuals.PubMedCrossRefGoogle Scholar
  8. 8.
    Baigent C, Patrono C: Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum 2003, 48:12- 20.PubMedCrossRefGoogle Scholar
  9. 9.
    Catella-Lawson F, Reilly MP, Kapoor SC, et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345:1809- 1817. Key paper evaluating the interaction between aspirin and ibuprofen, acetaminophen, or rofecoxib with respect to platelet inhibition in healthy individuals. This paper summarizes the current biologic understanding of the potential interactions between aspirin and NSAIDs, in particular ibuprofen.PubMedCrossRefGoogle Scholar
  10. 10.
    MacDonald TM, Wei L: Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003, 361:573- 574.PubMedCrossRefGoogle Scholar
  11. 11.
    Kurth T, Glynn RJ, Walker AM, et al.: Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003, 108:1191- 1195. Study that evaluated the interaction between aspirin and NSAIDs on first MI. This study evaluated different frequency of NSAID use and used randomized data on aspirin.PubMedCrossRefGoogle Scholar
  12. 12.
    Curtis JP, Wang Y, Portnay EL, et al.: Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. Br Med J 2003, 327:1322- 1323.CrossRefGoogle Scholar
  13. 13.
    Patel TN, Goldberg KC: Use of aspirin and Ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med 2004, 164:852- 856.PubMedCrossRefGoogle Scholar
  14. 14.
    Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez- Perez A: Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004, 109:3000- 3006. Large prospective case-control study that evaluated the effect of specific NSAIDs on the risk for acute MI and death from CHD. This study did not find risk reduction of NSAIDs on the occurrence of MI or a deleterious interaction between aspirin and NSAIDs.CrossRefGoogle Scholar
  15. 15.
    del Rincon ID, Williams K, Stern MP, et al.: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737- 2745.PubMedCrossRefGoogle Scholar
  16. 16.
    Solomon DH, Karlson EW, Rimm EB, et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107:1303- 1307.PubMedCrossRefGoogle Scholar
  17. 17.
    Fischer LM, Schlienger RG, Matter C, et al.: Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004, 93:198- 200.PubMedCrossRefGoogle Scholar
  18. 18.
    Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232- 235.PubMedGoogle Scholar
  19. 19.
    Buring JE, Hennekens CH, for the Women’s Health Study Research Group: Women’s Health Study: rationale and background. J Myocardial Ischemia 1992, 4:30- 40.Google Scholar
  20. 20.
    Buring JE, Hennekens CH, for the Women’s Health Study Research Group: The Women’s Health Study: summary of the study design. J Myocardial Ischemia 1992, 4:27- 29.Google Scholar
  21. 21.
    UK-TIA Study Group: United Kingdom Transient Ischemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991, 54:1044- 1054.CrossRefGoogle Scholar
  22. 22.
    US Preventive Services Task Force: Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002, 136:157- 160.Google Scholar
  23. 23.
    Pearson TA, Blair SN, Daniels SR, et al.: AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 2002, 106:388- 391.PubMedCrossRefGoogle Scholar
  24. 24.
    Eidelman RS, Lamas GA, Hennekens CH: The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease. Arch Intern Med 2002, 162:2033–2036.PubMedCrossRefGoogle Scholar
  25. 25.
    Schafer AI: Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995, 35:209- 219.PubMedGoogle Scholar
  26. 26.
    Pedersen AK, FitzGerald GA: Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing. Clin Pharmacol Ther 1985, 37:36- 42.PubMedCrossRefGoogle Scholar
  27. 27.
    Solomon DH, Glynn RJ, Levin R, Avorn J: Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch Intern Med 2002, 162:1099- 1104.PubMedCrossRefGoogle Scholar
  28. 28.
    Ray WA, Stein CM, Hall K, et al.: Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002, 359:118- 123.PubMedCrossRefGoogle Scholar
  29. 29.
    Pope JE, Anderson JJ, Felson DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993, 153:477- 484.PubMedCrossRefGoogle Scholar
  30. 30.
    Johnson AG, Nguyen TV, Day RO: Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121:289- 300.PubMedGoogle Scholar
  31. 31.
    Curhan GC, Willett WC, Rosner B, Stampfer MJ: Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002, 162:2204- 2208.PubMedCrossRefGoogle Scholar
  32. 32.
    Dedier J, Stampfer MJ, Hankinson SE, et al.: Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002, 40:604- 608.PubMedCrossRefGoogle Scholar
  33. 33.
    Murata T, Ushikubi F, Matsuoka T, et al.: Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997, 388:678- 682.PubMedCrossRefGoogle Scholar
  34. 34.
    Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286:954- 959.PubMedCrossRefGoogle Scholar
  35. 35.
    FitzGerald GA, Patrono C: The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001, 345:433- 442.PubMedCrossRefGoogle Scholar
  36. 36.
    Hermann M, Camici G, Fratton A, et al.: Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003, 108:2308- 2311.PubMedCrossRefGoogle Scholar
  37. 37.
    Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520- 1528. Randomized trial comparing the gastrointestinal side effects of rofecoxib and naproxen. In addition, the study found different effects of the two drugs with respect to CVD.PubMedCrossRefGoogle Scholar
  38. 38.
    Rahme E, Pilote L, LeLorier J: Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002, 162:1111- 1115.PubMedCrossRefGoogle Scholar
  39. 39.
    Watson DJ, Rhodes T, Cai B, Guess HA: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002, 162:1105- 1110.PubMedCrossRefGoogle Scholar
  40. 40.
    Konstam MA, Weir MR, Reicin A, et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001, 104:2280- 2288.PubMedGoogle Scholar
  41. 41.
    Reicin AS, Shapiro D, Sperling RS, et al.: Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal antiinflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 2002, 89:204- 209.PubMedCrossRefGoogle Scholar
  42. 42.
    Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247- 1255.PubMedCrossRefGoogle Scholar
  43. 43.
    White WB, Faich G, Whelton A, et al.: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002, 89:425- 430.PubMedCrossRefGoogle Scholar
  44. 44.
    Solomon DH, Schneeweiss S, Glynn RJ, et al.: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004, 109:2068- 2073.PubMedCrossRefGoogle Scholar
  45. 45.
    Loll PJ, Picot D, Ekabo O, Garavito RM: Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry 1996, 35:7330- 7340.PubMedCrossRefGoogle Scholar
  46. 46.
    Loll PJ, Picot D, Garavito RM: The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995, 2:637- 643.PubMedCrossRefGoogle Scholar
  47. 47.
    Livio M, Del Maschio A, Cerletti C, de Gaetano G: Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 1982, 23:787- 796.PubMedCrossRefGoogle Scholar
  48. 48.
    Rao GH, Johnson GG, Reddy KR, White JG: Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 1983, 3:383- 388.PubMedGoogle Scholar
  49. 49.
    Wilner KD, Rushing M, Walden C, et al.: Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 2002, 42:1027- 1030.PubMedGoogle Scholar
  50. 50.
    Steering Committee of the Physicians’ Health Study Research Group: Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989, 321:129- 135.CrossRefGoogle Scholar
  51. 51.
    Kimmel SE, Strom BL: Giving aspirin and ibuprofen after myocardial infarction. Br Med J 2003, 327:1298- 1299.CrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Tobias Kurth
    • 1
  • Charles H. Hennekens
  • Julie E. Buring
  • J. Michael Gaziano
  1. 1.Brigham and Women’s Hospital, Division of AgingBostonUSA

Personalised recommendations